The largest dataset to date stems from the prospective TRANSCEND CLL 004 phase I trial which tested lisocabtagene-maraleucel, a CD19-CAR, in 137 patients with r/r CLL and at least two lines of previous therapy, including a BTKI. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.